ACT Genomics

Is MSI Testing Using NGS Data Accurate?

US FDA approves treatment for cancers with high microsatellite instability (MSI-H) highlight the importance of MSI testing in cancer treatment ; more and more companies adopting to use NGS data for MSI assessment, and the biggest benefit of NGS-based MS

SG MSL Team of ACT Genomics 2020-10-13

Ovarian Cancer Patient: Ms. Chang

While fighting ovarian cancer for 18 years, Ms. Chang underwent several rounds of chemotherapy and surgery. At her last check-up, her cancer was found to have metastasized. She was at the point of accepting her fate when her attending doctor recommended genomic profiling, which led to a treatment recommendation that had not previously been considered.

ACTG 2020-12-24

Squamous Cell Skin Cancer Patient: Ms. Chen

The family members of 87-year-old Ms. Chen were reluctant that she be made to endure another surgery when her cancer relapsed owing to her age and effects of previous surgeries. Genomic profiling was then explored with her doctor to identify if she might be a candidate of immunotherapy. Fortunately, she is.

ACTG 2020-10-26

Negative hyper-selection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial

The phase III PARADIGM trial demonstrated that hyper-selected patients with no gene alterations would tend to be more beneficial with panitumumab than bevacizumab regardless of primary tumor sidedness.

2023-03-17

Negative hyper-selection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial

UNITE Study - Identified potential molecular biomarkers of response to Enfortumab Vedotin in advance urothelial cancer

A retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) database was presented at the 2023 ASCO Genitourinary Cancers Symposium. Through the next generation sequencing, the study analyzed several molecular biomarkers to identify the correlation between specific biomarkers and the efficacy of enfortumab vedotin.

2023-03-17

UNITE Study - Identified potential molecular biomarkers of response to Enfortumab Vedotin in advance urothelial cancer

Combination of KRAS G12C inhibitor adagrasib with immune checkpoint inhibitor pembrolizumab showed preliminary efficacy in patients with KRAS G12C-mutated NSCLC

The phase 1b KRYSTAL-1 and phase 2 KRYSTAL-7 studies demonstrated that the combination of adagrasib (the second KRAS G12C inhibitor to receive FDA accelerated approval) and pembrolizumab (an immune checkpoint inhibitor) had antitumor activity in patients with NSCLC.

2023-03-17

Combination of KRAS G12C inhibitor adagrasib with immune checkpoint inhibitor pembrolizumab showed preliminary efficacy in patients with KRAS G12C-mutated NSCLC

Neratinib plus fulvestrant plus trastzuzumab is a promising combination for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (mBC): results from the phase II SUMMIT trial

There is a promising combination of neratinib plus fulvestrant plus trastzuzumab (N+F+T) to patients with HR+/HER2-/HER2mut metastatic breast cancer, who pretreated with CDK4/6 inhibitor.

2023-02-14

Neratinib plus fulvestrant plus trastzuzumab is a promising combination for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (mBC): results from the phase II SUMMIT trial

VIDEOS

不同地區人種的基因特性對癌症治療有何重要性？

ACTG Blog

Is MSI Testing Using NGS Data Accurate?

Ovarian Cancer Patient: Ms. Chang

Squamous Cell Skin Cancer Patient: Ms. Chen

CLINICAL NEWS

Negative hyper-selection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial

UNITE Study - Identified potential molecular biomarkers of response to Enfortumab Vedotin in advance urothelial cancer

Combination of KRAS G12C inhibitor adagrasib with immune checkpoint inhibitor pembrolizumab showed preliminary efficacy in patients with KRAS G12C-mutated NSCLC

Neratinib plus fulvestrant plus trastzuzumab is a promising combination for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (mBC): results from the phase II SUMMIT trial

VIDEOS

What are the benefits of genetic testing for cancer?

ACT Genomics received the Best Practice Award from Frost & Sullivan

REGULATORY

Drug Regulatory Status Mar 2023

Drug Regulatory Status Feb 2023

Drug Regulatory Status Jan 2023